Cystatin C-based eGFR predicts cardiovascular disease in patients with overweight/obesity and hyperglycemia.
Keita SuzukiHiromasa TsujiguchiAkinori HaraHiroyuki NakamuraKazuhiko KotaniMitsuhiko NodaHajime YamakageNoriko Satoh-AsaharaToshinari TakamuraPublished in: Obesity science & practice (2022)
UMIN000000559.
Keyphrases
- weight loss
- cardiovascular disease
- weight gain
- small cell lung cancer
- type diabetes
- epidermal growth factor receptor
- insulin resistance
- metabolic syndrome
- tyrosine kinase
- high fat diet induced
- body mass index
- physical activity
- cardiovascular risk factors
- cardiovascular events
- diabetic rats
- skeletal muscle
- oxidative stress